Literature DB >> 34343865

Emerging roles for IL-6 family cytokines as positive and negative regulators of ectopic lymphoid structures.

David G Hill1, Amy Ward1, Lindsay B Nicholson1, Gareth W Jones2.   

Abstract

IL-6 family cytokines display broad effects in haematopoietic and non-haematopoietic cells that regulate immune homeostasis, host defence, haematopoiesis, development, reproduction and wound healing. Dysregulation of these activities places this cytokine family as important mediators of autoimmunity, chronic inflammation and cancer. In this regard, ectopic lymphoid structures (ELS) are a pathological hallmark of many tissues affected by chronic disease. These inducible lymphoid aggregates form compartmentalised T cell and B cell zones, germinal centres, follicular dendritic cell networks and high endothelial venules, which are defining qualities of peripheral lymphoid organs. Accordingly, ELS can support local antigen-specific responses to self-antigens, alloantigens, pathogens and tumours. ELS often correlate with severe disease progression in autoimmune conditions, while tumour-associated ELS are associated with enhanced anti-tumour immunity and a favourable prognosis in cancer. Here, we discuss emerging roles for IL-6 family cytokines as regulators of ELS development, maintenance and activity and consider how modulation of these activities has the potential to aid the successful treatment of autoimmune conditions and cancers where ELS feature.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ectopic Lymphoid Structures; Interleukin-11; Interleukin-27; Interleukin-6; Leukaemia inhibitory factor; Oncostatin-M; Tertiary Lymphoid Structures

Mesh:

Substances:

Year:  2021        PMID: 34343865     DOI: 10.1016/j.cyto.2021.155650

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

1.  Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.

Authors:  Felice Rivellese; Anna E A Surace; Katriona Goldmann; Elisabetta Sciacca; Cankut Çubuk; Giovanni Giorli; Christopher R John; Alessandra Nerviani; Liliane Fossati-Jimack; Georgina Thorborn; Manzoor Ahmed; Edoardo Prediletto; Sarah E Church; Briana M Hudson; Sarah E Warren; Paul M McKeigue; Frances Humby; Michele Bombardieri; Michael R Barnes; Myles J Lewis; Costantino Pitzalis
Journal:  Nat Med       Date:  2022-05-19       Impact factor: 87.241

2.  New-Generation Heterocyclic Bis-Pentamethinium Salts as Potential Cytostatic Drugs with Dual IL-6R and Mitochondria-Targeting Activity.

Authors:  Veronika Talianová; Zdeněk Kejík; Robert Kaplánek; Kateřina Veselá; Nikita Abramenko; Lukáš Lacina; Karolína Strnadová; Barbora Dvořánková; Pavel Martásek; Michal Masařík; Magdalena Houdová Megová; Petr Bušek; Jana Křížová; Lucie Zdražilová; Hana Hansíková; Erik Vlčák; Vlada Filimonenko; Aleksi Šedo; Karel Smetana; Milan Jakubek
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

Review 3.  Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope.

Authors:  Weili Jia; Tianchen Zhang; Qianyun Yao; Jianhui Li; Ye Nie; Xinjun Lei; Zhenzhen Mao; Yanfang Wang; Wen Shi; Wenjie Song
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 4.  Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?

Authors:  Liang Han; Zhe Chen; Kun Yu; Jiahui Yan; Tingting Li; Xin Ba; Weiji Lin; Yao Huang; Pan Shen; Ying Huang; Kai Qin; Yinhong Geng; Yafei Liu; Yu Wang; Shenghao Tu
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.